Surrozen (SRZN) Net Equity Issued and Repurchased (2021 - 2026)
Surrozen (SRZN) posted quarterly Net Equity Issued and Repurchased of $50.0 million for Q1 2026, down 34.54% year-over-year from $76.4 million in Q1 2025, and up 1328.16% quarter-over-quarter from $3.5 million in Q4 2025.
Analysis
Surrozen (SRZN) Net Equity Issued and Repurchased (2021 - 2026) Analysis & Trends
Surrozen's Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $50.0 million for Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased fell 34.54% year-over-year to $50.0 million; the TTM figure through Mar 2026 stood at $48.3 million (down 47.73% YoY), while the FY2025 annual figure was $74.7 million, up 365.64% from the prior year.
- Net Equity Issued and Repurchased for Q1 2026 stood at $50.0 million, up from $3.5 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $76.4 million in Q1 2025, with the low at -$5.2 million in Q2 2025.
- The 3-year median for Net Equity Issued and Repurchased is $9.8 million (2024), against an average of $23.5 million.
- The sharpest annual moves came in 2025 and 2026: Net Equity Issued and Repurchased plunged 132.32% in 2025, then plunged 34.54% in 2026.
- Surrozen's Net Equity Issued and Repurchased stood at -$1000.0 in 2024, then surged by 350200.0% to $3.5 million in 2025, then soared by 1328.16% to $50.0 million in 2026.
- Business Quant data shows SRZN's Net Equity Issued and Repurchased at $50.0 million in Q1 2026, $3.5 million in Q4 2025, and -$5.2 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Surrozen | 263.35 Mn | 263.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 50.00 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Jun 30, 2025 | -5.19 Mn |
| Mar 31, 2025 | 76.39 Mn |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | 16.04 Mn |
| Dec 31, 2021 | 125,000.00 |